Vitreoretinal Traction Syndrome Clinical Trial
Official title:
An Open Label Sequential Dose Response Observational Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)
Verified date | June 2019 |
Source | Bausch & Lomb Incorporated |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Plasmin is expected to create a posterior vitreous detachment (PVD) when injected directly into the eye. The pharmacological creation of a PVD may be beneficial in helping to treat a variety of conditions.
Status | Terminated |
Enrollment | 4 |
Est. completion date | June 2007 |
Est. primary completion date | May 2007 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients who are in need of a vitrectomy. Exclusion Criteria: - A PVD in the study eye as assessed by the investigator using ophthalmic and alternative examination techniques. - A history of vitrectomy in the study eye. - A media opacity that precludes quality examination of the vitreous and fundus in the study eye. |
Country | Name | City | State |
---|---|---|---|
United States | University Hospitals of Cleveland | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
Bausch & Lomb Incorporated |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Presence of a Posterior Vitreous Detachment (PVD) | Presence of posterior vitreous detachment evaluated durning virectomy | 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00348439 -
Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment
|
Phase 2 |